Karyopharm Therapeutics | KPTI - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 695M 1.12B 2026-03
Abbott USD 1.08B 699M 2026-03
Amgen USD 1.82B 486M 2026-03
AstraZeneca USD 3.08B 754M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Incyte USD 303.33M 4.05M 2026-03
J&J USD 5.24B 119M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
MacroGenics USD -14.16M 30.98M 2025-12
Merck USD -4.24B 7.2B 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Novartis USD 3.16B 747M 2026-03
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD 2.69B 4.34B 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Takeda JPY 103.64B 115.44B 2025-12
Tectonic Therapeutic USD -19.23M 186K 2025-12
TG Therapeutics USD 23.04M 367.86M 2025-12
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Xencor USD -6.65M 626K 2025-12